Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

Presentation ESC 2025

ABC-AF study: Pragmatic registry-based randomised controlled trial of personalised treatment to reduce stroke or death in atrial fibrillation

Presenter: Jonas Oldgren

August 30, 2025

Presentation ESC 2024

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Presenter: Manesh R. Patel

September 01, 2024

Presentation AHA 2023

AZALEA-TIMI 71

Presenter: Christian T. Ruff

November 15, 2023

Presentation ESC 2021

Implantable Loop Recorder to Detect Atrial Fibrillation and Prevent Stroke (The LOOP Study): A Randomised Controlled Trial

Presenter: Jesper Hastrup Svendsen

August 31, 2021

Presentation CACI 2019

Caso clínico: Estrategias no farmacológicas de prevención cardioembólica en la fibrilación auricular

Presenter: Ricardo Costantini

November 29, 2019

Presentation CACI 2019

Prevención del Stroke en Fibrilación Auricular: Estrategia Endovascular

Presenter: Aníbal Damonte

November 29, 2019

Presentation Controversies and Advances 2019

Perils of Digital Health

Presenter: John Mandrola

November 15, 2019

Presentation LAA 2017

Electrical/Ablation Approaches to AFib: Competitive or Complementary With LAA Closure?

Presenter: Vivek Y. Reddy

July 21, 2017

Presentation SIF 2017

Thromboembolic Prophylaxis in Atrial Fibrillation

Presenter: Samir Kapadia

March 09, 2017

Presentation EuroPCR 2016

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Presenter: Jens Erik Nielsen-Kudsk

May 20, 2016

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation

LAA Occlusion for Stroke Prevention in A-Fib

Presenter: Apostolos Tzikas

January 29, 2015

Presentation

Atrial Fibrillation, Stroke, and Mortality Rates Following TAVI

Presenter: Lior Yankelson

October 13, 2014

Presentation TCT 2014

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini

September 14, 2014

Presentation

Cryptogenic Stroke and Underlying A-fib

Presenter: Tomasso Sanna

July 01, 2014

Presentation

A-fib in Patients with Cryptogenic Stroke or TIA

Presenter: D.J. Gladstone

July 01, 2014

Presentation

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Presenter: David R. Holmes Jr.

June 30, 2014

Presentation

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Presenter: Robert P. Giugliano

June 24, 2014

Presentation ECHO 2014

Clinical Decision Making in Stroke and Atrial Fibrillation (Including Closure Devices)

Presenter: James D. Thomas

April 11, 2014

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

Advertisement

ABC-AF study: Pragmatic registry-based randomised controlled trial of personalised treatment to reduce stroke or death in atrial fibrillation

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

AZALEA-TIMI 71

Implantable Loop Recorder to Detect Atrial Fibrillation and Prevent Stroke (The LOOP Study): A Randomised Controlled Trial

Caso clínico: Estrategias no farmacológicas de prevención cardioembólica en la fibrilación auricular

Prevención del Stroke en Fibrilación Auricular: Estrategia Endovascular

Perils of Digital Health

Electrical/Ablation Approaches to AFib: Competitive or Complementary With LAA Closure?

Thromboembolic Prophylaxis in Atrial Fibrillation

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

LAA Occlusion for Stroke Prevention in A-Fib

Atrial Fibrillation, Stroke, and Mortality Rates Following TAVI

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Cryptogenic Stroke and Underlying A-fib

A-fib in Patients with Cryptogenic Stroke or TIA

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Clinical Decision Making in Stroke and Atrial Fibrillation (Including Closure Devices)

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content